Fellowship for CAR-T Study
Targeting Mechanisms of Treatment Resistance in Diffuse Midline Glioma
Targeting Adaptive Immune Niche in the Skull Bone Marrow for Novel Immunotherapy
Enhancing CAR-T Therapy through Immunomodulation of the Tumor Microenvironment by Blocking TIM-3
Investing DIPG Tumor Dependencies on Branched Chain Amino Acid Catabolism through Therapeutic Dietary Restriction
Inhibition of Mitochondrial ROS Scavenging as a Novel Treatment for DMG
Engineering Enhanced Gamma Delta T-Cells to Overcome DIPG Immune Resistance
Harnessing Oncolytic Adenoviruses for Targeted Diffuse Midline Glioma Therapy
Elucidating the Mechanism of EGFR Mediated Resistance to ONC201 in H3K27M Mutant Diffuse Midline Glioma
Lipid Dependent Mechanisms Underlying Cell State Specification in H3K27M Diffuse Midline Glioma
Targeting Energy Metabolism in Diffuse Intrinsic Pontine Glioma
Development of Novel Nanoelectronics-based Treatment for Diffuse Intrinsic Pontine Glioma: A Multifaceted Technology to Overcome Treatment Challenges
Targeting DNA Replication Stress to Induce Innate Inflammation in Diffuse Midline Gliomas with H3K27M Mutations
Attacking the Achilles’ Heel of Diffuse Midline Gliomas with Innovative H3K27M-Targeting Chemical Probes
Tracing the Origins of DIPG
Multimodal Systems for Molecular Profiling and Therapeutic Tracking of DIPG
Immunometabolic Modulation of Diffuse Midline Glioma Response to Therapy
Single Cell Epi-Multiomic Characterization of the Cellular Hierarchy in H3K27M Diffuse Midline Glioma to Leverage Intrinsic Tumor Cell Plasticity Towards Novel Therapeutic Targets
Therapeutic Targeting of H3K27M-Driven Folate Metabolism in DIPGs
Investigation of the Efficacy of Combinatorial ONC206 and B7-H3 CAR T Cells Against DIPG/DMG Models
Targeting Voltage-Sensitive Mechanisms of DIPG Growth
Molecular Elucidation of DIPG Surface Signaling in Response to NLGN3
Identifying DIPG Vulnerabilities Conferred by Whole-Arm Chromosomal Alterations
Combining Virotherapy and Anti-GD2 CAR T Cells for Diffuse Midline Glioma
Immunomodulation of the Tumor Microenvironment in DIPG by Oncolytic Virotherapy
Investigating the Roles of Lactate as Metabolic Fuel and Epigenetic Modifier in H3K27M DIPGs
Targeting Communication Networks in DIPG
Assessing the Potential of Givinostat, Paxalisib and Radiotherapy Combination Therapies for the Treatment of DIPG
Identifying and Targeting Developmental Vulnerabilities of Diffuse Midline Gliomas
Engineering Enhanced GD2 CAR T-Cells to Overcome DIPG Immune Resistance
Defining the Tumor Intrinsic and Regional Landscape of Therapeutic RNA-Nanoparticle Transduction and Immune Activation Following Intravenous Administration in DIPG
Reprogramming the Tumor Microenvironment in DIPG with Engineered iPSC-NK Cells to Improve Immunotherapy
Targeting Aberrant RNA Translation in DIPG
Immune Determinants of GD2 CAR T-Cell Activity in Patients with DIPG
In Vivo Imaging of Diffuse Midline Gliomas
C7R-GD2 CAR T-Cells for DMG: Clinical Trial of Dual Route Strategy
CLIA certified assays for plasma-based disease response monitoring in histone mutant gliomas
CD155 as a Novel Regulator of Cell Growth and Immune Evasion in DIPG
Deciphering Aberrant RNA Translation in DIPG
Advancing data analyses of DMG tumors
Targeting Combined Metabolic and Epigenetic Pathways H3K27M DIPG
Exploring H3K27ac Deregulation as Therapeutically Actionable in Histone Mutant Pediatric DIPG
Neurophysiological Small Molecule Screen for Inhibitors of Neuron-to-DIPG Communication
Remodeling Lipid Metabolism for Therapeutic Differentiation of H3K27M DIPG
Integrating Systemic and Local Therapeutic Vulnerabilities to Improve the Treatment of Diffuse Midline Glioma
Tumor-Targeted pan-RAS Inhibition as a Novel Therapy for Diffuse Intrinsic Pontine Glioma (DIPG)
Determining the Effect of ONC201 on DIPG Cellular Metabolism and Targeting Mechanisms of Resistance
Exploring copper chelation as a novel epigenetic therapeutic strategy for DIPG
Targeting the electrical vulnerabilities of DIPG by modulating the neuronal microenvironment
Combinatorial targeting of Cyclin-Dependent Kinases in DIPG
Dissecting mechanisms of radio resistance associated with p53 mutations in DIPG
A clinically translatable nanotherapeutic approach to enhance BBB drug delivery in DIPG
Development of a Comprehensive Direct Drug Delivery Platform for the Treatment of Diffuse Midline Glioma
Targeting Diffuse Midline Gliomas with Rational Combination Therapy
Targeted Protein Degradation of LSD1 as a Therapeutic Strategy in DIPG
Therapeutic targeting of the PBAF chromatin remodeling complex in diffuse intrinsic pontine gliomas
Supporting CAR T Trial: Neuro-Immuno-Oncology (NIO) fellowship program
Epigenetic regulation of phenotypic plasticity in DIPG
Targeting T-cell intrinsic and extrinsic regulators to improve T cell therapies in DIPGs
Epigenetically activated ID1 is a key transcriptional regulator of DIPG Invasion and is targetable with cannabidiol.
Use of H3(K27M) – Driven Zebrafish Models to Identify Targetable Vulnerabilities in DIPG
Targeting DIPG using novel CAR-T cell therapy
Oncolytic Immunotherapy for Diffuse Intrinsic Pontine Gliomas
Metabolic therapies for DIPGs
MYC activation in Diffuse Intrinsic Pontine Gliomas
MYC activation in Diffuse Intrinsic Pontine Gliomas
Viroimmunotherapeutic strategies to heat up DIPG microenvironment. A comprehensive approach to unleash anti-tumor immune response.
Targeting the electrophysiological response to GABA in DIPG through neurological and neuropsychiatric drug repurposing
DMG-ACT Trial
Enhancing the efficacy of radiation therapy for DIPG
Interrogating the role of POU Transcription Factor Driven ERV Activation in H3K27M Diffuse Midline Glioma
ONC201 in DIPG; establishing mechanism, enhancing efficacy and determining long-term phenotypic consequences
Unlocking oncogene addition to identify synergistic treatment targets for the treatment of DIPG
Dependence of DIPGs on DNA polymerase for DNA repair defines a new therapeutic target.
Next-generation CAR T cell therapies for treatment of DIPG, utilizing sequential ‘prime-and-kill’ circuits to achieve safe and effective tumor targeting
Targeting DIPGs by interrupting metabolic pathways
Dissecting mechanisms of H3K27M oncohistone function in DIPG
Mechanistic studies on the WNT5A signal pathway in DIPG tumor
Targeting epigenetically induced vulnerabilities in DIPG
Therapeutic Targeting of Metabolic Vulnerabilities in DIPG
Optimal combinatorial targeting of HDAC inhibition and radiation in DIPG
Characterizing long non-coding RNAs as therapeutic targets in diffuse intrinsic pontine glioma
MIC2 inhibition mediated apoptosis in DIPG
Targeting Cancer Stem Cells in DIPG.
Use of a Long Non-coding RNA (lncRNA) as a Therapeutic Target in DIPG.
Targeting metabolic regulation of the epigenome in DIPG
Therapeutic targetiing of the disrupted metabolic state in DIPG to induce ferroptotic cell death.
Mass Spectroscopy Instrument
Expanded Access Program for ONC201
Supporting Innovative DIPG Research: Dr. Mark Souweidane’s Lab
Supporting Groundbreaking DIPG Research: Dr. Cynthia Hawkins’ Lab
The Tumor Microtube Network in DIPG: Targeting a Possible ‘Achilles Heel’ Required to Defeat DIPG.
Enhancing efficacy of adoptive immunotherapy against DIPG using hematopoietic cells.
Recombinant Attenuated Poliovirus Immunization Vectors Targeting H3.3(K27M) in DIPG.
Prioritizing PPM1D mutations as a target for new DIPG therapies
Targeting chromatin regulation to treat DIPT
Dissection of ATRX in Diffuse Intrinsic Pontine Glioma